首页|KIAA1199基因和Linc00673基因对非小细胞肺癌化疗疗效的预测价值分析

KIAA1199基因和Linc00673基因对非小细胞肺癌化疗疗效的预测价值分析

扫码查看
目的 探讨KIAA1199 基因和Linc00673 基因在非小细胞肺癌患者化疗前后的表达变化,并进一步评估这两个基因作为分子标志物在预测化疗疗效方面的潜在价值.方法 选取 2019 年 8 月至 2021 年 8 月石家庄市第三医院和华北医疗健康集团峰峰总医院收治的 58 例Ⅲ-Ⅳ期非小细胞肺癌患者,分别在治疗前 2 d和治疗两个周期后获取患者外周血PBMC细胞,检测KIAA1199 基因、Linc00673 基因表达水平,统计患者化疗疗效,并通过ROC曲线分析KIAA1199 基因、Linc00673 基因作为分子标志物预测化疗疗效的价值.结果 经两个周期化疗后,58 例患者中 20 例出现病情进展,占比 34.48%.qPCR结果显示,治疗前,进展与未进展患者间KIAA1199 基因、Linc00673 基因表达水平比较,差异均无统计学意义(P>0.05);治疗后,相比于进展患者,未进展患者KIAA1199 基因、Linc00673 基因表达水平均显著降低(P<0.01).ROC曲线分析结果显示,联合检测的AUC均显著高于KIAA1199 基因和Linc00673 基因(Z=3.054、5.178,P<0.05).结论 在非小细胞肺癌化疗患者中,KIAA1199 基因、Linc00673 基因的表达因疗效不同而呈现显著差异,其中KIAA1199 基因更适宜作为预测化疗疗效的生物标志物.
Predictive Value of KIAA1199 and Linc00673 Genes on Chemotherapy Efficacy in Non-small Cell Lung Cancer
Objective To explore the expression changes of KIAA1199 and Linc00673 genes in non-small cell lung cancer patients before and after chemotherapy,and to further evaluate the potential value of these two genes as molecular markers in predicting chemotherapy efficacy.Methods A total of 58 patients with stage Ⅲ-ⅣNSCLC admitted to the Third Hospital of Shijiazhuang and Fengfeng General Hospital of North China Medical Health Group from August 2019 to August 2021 were selected.Peripheral blood PBMCs were collected from patients 2 days before treatment and after two cycles of treatment to detect the expression levels of KIAA1199 and Linc00673 genes.The chemotherapy efficacy of patients was statistically analyzed,and the value of KIAA1199 and Linc00673 genes as molecular markers in predicting chemotherapy efficacy was assessed using ROC curve analysis.Results After 2 cycles of chemotherapy,20 out of 58 patients showed disease progression,accounting for 34.48%.qPCR results showed no statistically significant difference in the expression levels of KIAA1199 and Linc00673 genes between progressed and non-progressed patients before treatment(P>0.05).After treatment,the expression levels of KIAA1199 and Linc00673 genes were significantly lower in non-progressed patients compared to progressed patients(P<0.01).ROC curve analysis showed that the AUC of combined detection was significantly higher than that of KIAA1199 gene and Linc00673 gene alone(Z=3.054,5.178,P<0.05).Conclusion In NSCLC patients undergoing chemotherapy,the expression of KIAA1199 and Linc00673 genes shows significant differences based on therapeutic efficacy,with KIAA1199 being more suitable as a biomarker for predicting chemotherapy efficacy.

Linc00673KIAA1199Non small cell lung cancerExpression levelEfficacy prediction

余会敏、辛鑫、梁志伟

展开 >

石家庄市第三医院介入科,河北 石家庄 050000

华北医疗健康集团峰峰总医院胸外科,河北 邯郸 056200

Linc00673 KIAA1199 非小细胞肺癌 表达水平 疗效预测

2025

昆明医科大学学报
昆明医学院

昆明医科大学学报

影响因子:0.829
ISSN:1003-4706
年,卷(期):2025.46(1)